Category - News

Developments

BioSight completes Phase 1/2a leukemia trial

Closely-held BioSight has completed patient treatment in its ongoing Phase 1/2a clinical study of Astarabine in acute leukemia patients and expects to report final results in coming months. The Phase 1/2a trial is an...

April 20, 2016

Developments

FDA rejects TransEnterix SurgiBot submission

The FDA has advised TransEnterix (NYSE MKT:TRXC) that its SurgiBot System does not meet the criteria for substantial equivalence based on the data and information submitted by the company in its 510(k) submission. “The...

April 20, 2016

Markets

Roth starts Foundation Healthcare at buy

Roth Capital Partners has initiated coverage of Foundation Healthcare (OTC:FDNH) with a “buy” rating and $6 price target. The stock closed at $3.05 on Monday. “The impetus for our buy rating is the potential of the...

April 19, 2016

Markets

Rodman starts Bio-Path at buy

Rodman & Renshaw has launched coverage of Bio-Path Holdings (NASDAQ:BPTH) with a “buy” rating and a 12-month price target of $5. The stock closed at $2.76 on Monday. “In our view, Bio-Path’s unique liposomal...

April 19, 2016

Markets

Rodman assumes coverage of Semler Scientific at buy

Rodman & Renshaw analyst Raghuram Selvaraju has assumed coverage of Semler Scientific (NASDAQ:SMLR) with a “buy” rating and $8 price target. The stock was quoted at $2.05 Friday afternoon. Semler’s 2015 revenue of...

April 16, 2016

Markets

Rodman assumes coverage of NephroGenex at neutral

Rodman & Renshaw analyst Raghuram Selvaraju has assumed coverage of NephroGenex (NASDAQ:NRX) with a “neutral” rating and without a price target. The stock was quoted at 40 cents Friday afternoon. The board of...

April 16, 2016

Developments

Titan Pharma presents Phase 3 Probuphine data

Titan Pharmaceuticals (NASDAQ:TTNP) has presented data from the last Phase 3 study of Probuphine, a six month subdermal buprenorphine implant for the long-term maintenance treatment of opioid addiction, at a poster...

April 15, 2016

Developments

Avivagen plans JV to sell OxC-beta in China

Avivagen (TSX-V:VIV) plans to collaborate with the Jintai group of companies for a joint venture to commercialize OxC-beta Livestock in China. The companies plan to create a Sino-Canadian joint venture company based in...

April 15, 2016

Markets

Canaccord starts CryoLife at buy

Canaccord Genuity has launched coverage of CryoLife (NYSE:CRY) with a “buy” rating and $14 yearend price target. The stock closed at $11 on Tuesday. “We recommend small-cap GARP (growth at a reasonable price) investors...

April 14, 2016

Developments

Soricimed to present four posters at AACR

Closely-held Soricimed Biopharma and collaborators plan to present four posters at the American Association of Cancer Research (AACR) annual meeting in New Orleans on April 16-20. The presentations are based on...

April 13, 2016

Category - News

Subscribe